Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures~* Currently taking a failing ARV regimen~* Plasma HIV-1 RNA ≥ 500 copies/mL but ≤ 100,000 copies/mL at screening~* Normal ECG~* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula for creatinine clearance~* Alanine aminotransferase (AST)/aspartate aminotransferase (AST) ≤ 5 × the upper limit of the normal range (ULN)~* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin~* Adequate hematologic function~* Serum amylase ≤ 5 × ULN~* Females may enter the study if it is confirmed that she is:~  * Not pregnant or nursing~ * Of non-childbearing potential (ie, have had a hysterectomy, both ovaries removed, medically documented ovarian failure, or are postmenopausal women \> 54 years of age with cessation \[for ≥ 12 months\] of previously occurring menses), or~ * Of childbearing potential and agrees to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following study drug dosing~    * Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.~* Males must agree to utilize a highly effective method of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from first dose throughout the study period and for 30 days following the last study drug dose.~* Males must agree to refrain from sperm donation from first dose until at least 30 days after the last study drug dose.~Key Exclusion Criteria:~* A new AIDS-defining condition diagnosed within the 30 days prior to screening~* Hepatitis B surface antigen (HBsAg) positive~* Hepatitis C antibody positive (individuals with positive hepatitis C virus (HCV) antibody and without detectable HCV RNA are permitted to enroll)~* History of integrase inhibitor use~* Screening or historical genotype reports shows Q151M or T69ins or more than 3 TAMs.~* Screening or historical genotype report shows resistance to integrase inhibitors~* Individuals experiencing decompensated cirrhosis~* Current alcohol or substance use~* History of malignancy within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Part 1, Day 1 and must not be anticipated to require systemic therapy during the study.~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Part 1, Day 1~* Any other clinical condition or prior therapy that would make the individual unsuitable for the study or unable to comply with dosing requirements~* Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial~* Receiving ongoing therapy with any disallowed medications, including any drugs not to be used with elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or known allergies to the excipients of E/C/F/TAF STR~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 Sentinel Cohort (TAF) (Type: EXPERIMENTAL): TAF + their current failing ARV regimen for 10 days in Part 1
- Part 1 Randomized Cohort (TAF) (Type: EXPERIMENTAL): Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
- Part 1 Randomized Cohort (Placebo) (Type: PLACEBO_COMPARATOR): Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
- Part 2 E/C/F/TAF+ATV (Type: EXPERIMENTAL): Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a \> 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete